Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. Vredenburgh JJ, et al. Among authors: marcello j. Clin Cancer Res. 2011 Jun 15;17(12):4119-24. doi: 10.1158/1078-0432.CCR-11-0120. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531816 Free PMC article. Clinical Trial.
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE 2nd, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Reardon DA, et al. Among authors: marcello je. Br J Cancer. 2009 Dec 15;101(12):1986-94. doi: 10.1038/sj.bjc.6605412. Epub 2009 Nov 17. Br J Cancer. 2009. PMID: 19920819 Free PMC article. Clinical Trial.
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Sathornsumetee S, et al. Among authors: marcello je. J Clin Oncol. 2008 Jan 10;26(2):271-8. doi: 10.1200/JCO.2007.13.3652. J Clin Oncol. 2008. PMID: 18182667 Free PMC article. Clinical Trial.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Vredenburgh JJ, et al. Among authors: marcello j. J Clin Oncol. 2007 Oct 20;25(30):4722-9. doi: 10.1200/JCO.2007.12.2440. J Clin Oncol. 2007. PMID: 17947719 Clinical Trial.
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Desjardins A, et al. Among authors: marcello j. Clin Cancer Res. 2008 Nov 1;14(21):7068-73. doi: 10.1158/1078-0432.CCR-08-0260. Clin Cancer Res. 2008. PMID: 18981004 Free PMC article. Clinical Trial.
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Reardon DA, et al. Among authors: marcello j. J Neurooncol. 2010 Jan;96(2):219-30. doi: 10.1007/s11060-009-9950-0. Epub 2009 Jun 28. J Neurooncol. 2010. PMID: 19562254 Free PMC article. Clinical Trial.
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Reardon DA, et al. Among authors: marcello j. J Neurooncol. 2011 Jan;101(1):57-66. doi: 10.1007/s11060-010-0217-6. Epub 2010 May 5. J Neurooncol. 2011. PMID: 20443129 Free PMC article. Clinical Trial.
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE 2nd, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Reardon DA, et al. Among authors: marcello j. J Neurooncol. 2011 Jun;103(2):371-9. doi: 10.1007/s11060-010-0403-6. Epub 2010 Sep 19. J Neurooncol. 2011. PMID: 20853132 Free PMC article. Clinical Trial.
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS. Vredenburgh JJ, et al. Among authors: marcello j. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):58-66. doi: 10.1016/j.ijrobp.2010.08.058. Epub 2010 Oct 30. Int J Radiat Oncol Biol Phys. 2012. PMID: 21036490 Clinical Trial.
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ. Desjardins A, et al. Among authors: marcello j. Cancer. 2012 Mar 1;118(5):1302-12. doi: 10.1002/cncr.26381. Epub 2011 Jul 26. Cancer. 2012. PMID: 21792866 Free article. Clinical Trial.
39 results